fromFast Company
2 weeks agoTrump unveils deal with Eli Lilly and Novo Nordisk to lower costs and expand coverage for obesity drugs
President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy. The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity in recent years. But access to the drugs has been a consistent problem for patients because of their cost - around $500 a month for higher doses - and insurance coverage has been spotty.
US politics